UPDATE 1-Roche sets sights on Novartis, Biogen as SMA trial hits target
November 11, 2019 at 03:23 AM EST
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.